Delivery of the full-length tumor antigen might be more successful in immunotherapy than single peptides and has the advantage that patients no longer need to be selected for their HLA type. In this study, we tested the in vitro induction of CAMEL/NY-ESO-ORF2-specific T cells by dendritic cells infected with an adenovirus (Ad) type 5 vector containing the fiber shaft and knob of human serotype Ad35 (Ad5F35 vector). Our data show induction of CD8 þ T cells specific for the known HLA-A*0201-binding CAMEL/ NY-ESO-ORF2 1-11 epitope by DC infected with Ad5F35-CAMEL, but not by DC pulsed with the recombinant CAMEL protein.
D
uring the last few years, an increasing number of tumor-specific antigens has been identified (reviewed in Wang and Rosenberg 1 ). This led to the development of immunotherapy strategies to stimulate T-cell responses specific for these tumor antigens. To date, melanoma patients are vaccinated with HLA class I-binding peptides derived from melanocytic differentiation antigens like MART-1/Melan-A, 2-4 gp100 [3] [4] [5] [6] [7] and tyrosinase, 3, 4, 7, 8 or cancer-testis antigens like MAGE-1, 4, 9, 10 MAGE-3 4, 11, 12 and NY-ESO-1. 13 These peptides are either injected alone 2, 3, 5, 6, 8, 11, 13 or pulsed on dendritic cells (DC), 4, 7, 9, 10, 12 which are believed to be the most potent antigen-presenting cells for the induction of T-cell responses in vivo. Recently, melanoma patients have been described to be treated by adoptive transfer of CD8 þ cytotoxic T lymphocytes (CTL), raised in vitro by autologous DC pulsed with HLA-A*0201-binding peptides derived from MART-1/Melan-A 14, 15 or gp100. 15 All the above-described clinical trials, however, fail to demonstrate a clear association between clinical and immunological responses.
Thus far, in most clinical trials, identified HLA class I-binding tumor antigenic peptides are used for the induction or stimulation of CD8 þ CTL responses. However, numerous in vitro and in vivo studies have shown that CD4 þ T helper cells contribute to the efficient induction of CD8 þ T-cell-mediated antitumor responses. [16] [17] [18] [19] Therefore, delivery of the full-length tumor antigen as protein, plasmid or viral vector encoding the entire tumor antigen might be more successful in future immunotherapies. Moreover, delivery of the entire tumor antigen leads to presentation of both known and unknown HLA class I-and -II-binding epitopes and is therefore broadly applicable to patients with different HLA types.
Several studies have demonstrated that tumor-specific CD8 þ T cells can be generated successfully in vitro [20] [21] [22] and in vivo 22, 23 by DC infected with subgroup C adenovirus type 2 (Ad2) and type 5 (Ad5) vectors encoding tumor antigens. Infection of DC with Ad2 and Ad5 vectors, however, is rather inefficient since DC lack expression of the coxsackie-adenovirus receptor (CAR), the high-affinity ligand for the fiber of subgroup C adenoviruses. 24 In contrast to subgroup C adenoviruses, subgroup B adenoviruses, like Ad35, have been described to efficiently infect hematopoietic cells due to binding to another, yet unknown, surface receptor. 25 In previous studies, Rea et al. 26 and Havenga et al.
demonstrated that DC were most efficiently infected with an Ad5 vector containing the fiber knob and shaft of Ad35 (Ad5F35 vectors) compared to the regular Ad5 vector and chimeric Ad5 vectors expressing the fiber shaft and knob of other subgroup B adenoviruses. The use of adenoviral vectors in gene therapy is limited by the presence of neutralizing antibodies in human individuals due to previous exposure to adenoviruses. These antibodies are mainly directed against the viral capsid proteins, that is, hexon, penton and fiber. 28, 29 Most antifiber antibodies are specific for the fiber knob and, in combination with antipenton antibodies, mediate the neutralizing activity of sera. 30 Besides antifiber and antipenton antibodies that can abrogate infection of the virus, antihexon antibodies can prevent viral escape from the endosome preventing the virus from reaching the nucleus. 31 As such, all three capsid proteins are important targets for neutralizing antibodies. In contrast to Ad2 and Ad5, natural infections with Ad35 in human individuals are very rare, 32 making the chimeric Ad5F35 vector perhaps less susceptible to elimination by pre-existing neutralizing antibodies.
CAMEL was identified as the target structure recognized by tumor-specific CTL isolated from peripheral blood of a melanoma patient by Aarnoudse et al.
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CAMEL is a 109-aa protein translated from the LAGE-1 gene 34 in an alternative open reading frame (ORF), starting at an ATG site located 40 bp downstream of the first ATG start site. LAGE-1 is highly homologous to tumor antigen NY-ESO-1. 35 Both genes are frequently coexpressed in various tumor types, like melanoma, breast carcinoma, prostate and bladder cancer, but silent in normal tissue except for testis. [34] [35] [36] Interestingly, the NY-ESO-1 gene has also been shown to be translated in an alternative ORF, resulting in a 58-aa NY-ESO-ORF2 protein, of which the N-terminal 54 aa are completely identical to CAMEL. 37 From both CAMEL and NY-ESO-ORF2, MHC class I-and II-presented epitopes have been described to be recognized by CD8 þ and CD4 þ T cells isolated from melanoma patients, indicating that these alternatively translated proteins are immunogenic in vivo. 33, 37, 38 In this study, mature DC infected with the chimeric Ad5F35 vector encoding tumor antigen CAMEL (Ad5F35-CAMEL) were tested for the in vitro induction of primary CD8 þ and/or CD4 þ T-cell responses against CAMEL in healthy donors. The data show that CD8 þ T cells specific for the previously identified HLA-A*0201-binding CAMEL/NY-ESO-ORF2 1-11 epitope could be induced by DC infected with Ad5F35-CAMEL. In one healthy donor, even CD8 þ T cells specific for a new HLA-B7-binding CAMEL/NY-ESO-ORF2 46-54 epitope were raised. Since CAMEL/ NY-ESO-ORF2-specific CD8 þ T cells were not induced by DC pulsed with rCAMEL protein, our data strongly support further development of immunotherapies using the chimeric Ad5F35 vector as a vehicle for gene transfer into DC.
Materials and methods

Cell lines
COS-1 cells and melanoma cell lines FM6 (gift from J Zeuthen, Copenhagen, Denmark), SK23 (gift from T Wo¨lfel, Mainz, Germany) and 518A2, were cultured in Dulbecco's Modified Eagle Medium (Invitrogen, Breda, The Netherlands) supplemented with 8% heat-inactivated fetal calf serum (FCS), 4 mM L-glutamine, 50 mg/ml penicillin and 50 mg/ml streptomycin. EBV-transformed B-lymphoblastic cell lines (EBV-B cells) were grown in RPMI-1640 (Invitrogen) with FCS, L-glutamine and antibiotics.
Peptides and recombinant protein
A total of 11 partially overlapping 20-and 22-mer peptides comprising the entire 109-aa CAMEL protein sequence were synthesized by solid-phase methods, using an automated multiple peptide synthesizer (Abimed AMS 422; Abimed Analysen-Technik, Langenfeld, Germany) and Fmoc chemistry. After reverse-phase HPLC analysis, peptides were dissolved in dimethylsulfoxide at 50 mg/ml and stored at À701C. From this stock solution, peptide was diluted in PBS to a final concentration of 1 mg/ml and stored at À201C.
Recombinant CAMEL protein (rCAMEL) was produced in a bacterial expression system. Briefly, a 349 bp LAGE-1 cDNA fragment was cloned in frame with an Nterminal (His) 10 -tag into the pET19b vector (Novagen, Madison, WI). This 349 bp fragment contains only the coding sequence for the alternatively translated CAMEL protein due to deletion of the first ATG start site. Escherichia coli strain BL21(DE3) (Stratagene, Amsterdam, The Netherlands) were transformed with pET19b-CAMEL and expression of the vector was induced by addition of 1 mM isopropyl-b-D-thiogalactoside (IPTG). After 4 hours, rCAMEL was purified from bacterial lysate by nickel-chelate chromatography using nickel-nitrilotriacetic acid agarose according to the manufacturer's instructions (Westburg, Leusden, The Netherlands). rCAMEL was eluted in 8 M urea, 100 mM NaH 2 PO 4 and 10 mM Tris, pH 4.5 and dialyzed in distilled water. After lyophilization, rCAMEL was dissolved in distilled water at 1 mg/ml and stored at À701C.
Adenoviral constructs
Ad5F35-CAMEL is a recombinant Ad5 vector modified to express the fiber shaft and knob of serotype Ad35 containing a 349 bp LAGE-1 cDNA fragment only coding for the alternatively translated CAMEL protein due to deletion of the first ATG start site. Ad5F35-CAMEL was generated and purified as described previously. 26, 39 Briefly, PER.C6t cells were cotransfected with a cosmid (pWE/Ad.AflII-rITR.Pac/Fib35) linearized with PacI and a plasmid (pAdapt) encoding 75 kb of Ad5 sequence of the left side of the Ad5 genome, whereby the E1 region is replaced by an expression cassette. The CAMEL antigen is under the control of the CMV promoter/enhancer. Recombinant virus was purified by CD8 þ T cells induced by Ad5F35-CAMEL-infected DC EH Slager et al cesium chloride density gradient centrifugation and the titer of the virus batch was determined by HPLC as described before.
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The Ad5-LAGE-1 and Ad5-NY-ESO-1 vectors are Ad5 vectors containing a 780 bp LAGE-1 and a 950 bp NY-ESO-1 cDNA fragment, respectively. The cDNA fragments were cloned into the Ad5 vector according to the method of He et al., 41 which is characterized by a recombination step in E. coli. The Ad5 vectors lack the E1 and E3 regions. Both vectors contain a CMV promoter/ enhancer to drive expression of the transgene and a separate CMV promoter/enhancer to drive expression of the GFP gene. The Ad5 vectors were propagated on packaging cell line PER.C6t.
Generation of dendritic cells
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood obtained from two healthy donors, who were HLA-typed as A1, A*0201, B7, B35 (donor 1) and A1, A*0201, B8, B13 (donor 2) using standard serological techniques. PBMC were depleted for T and B cells using CD2-and CD19-dynabeads (Dynal, Oslo, Norway) and cultured in six-well plates (2 Â 10 6 cells/well) in AIM-V (Invitrogen) with 116 mg/ml Larginine, 36 mg/ml L-asparagine and 215 mg/ml L-glutamine (AAG) and antibiotics, supplemented with 500 U/ml IL-4 (PeproTech Inc., Rocky Hill, NJ) and 800 U/ml GM-CSF (Behringwerke, Marburg, Germany) for 6 days. Immature DC were harvested and seeded at 10 6 cells/well in 24-well plate in 1 ml AIM-V containing activating anti-CD40 Ab (1 mg/ml; Cymbus Biotechnology, Chandlers Ford, UK), IL-4 (500 U/ml) and GM-CSF (800 U/ml). After overnight incubation with the activating anti-CD40 Ab, Ad5F35-CAMEL vector was added to the mature DC at doses ranging from 2.5 Â 10 3 to 6 Â 10 3 virus particles (VP)/cell. After 2 hours at 371C, 1 ml AIM-V supplemented with anti-CD40 Ab, IL-4 and GM-CSF as described above was added. The Ad5F35-CAMELinfected, mature DC were used as stimulators 24 hours after infection. For loading with rCAMEL protein, immature DC were pulsed with 10 mg/ml rCAMEL for 4 hours at 371C and subsequently matured for 2 days in AIM-V containing the anti-CD40 Ab, IL-4 and GM-CSF as described above. For peptide pulsing, immature DC were incubated for 2 days in AIM-V containing the anti-CD40 Ab, IL-4 and GM-CSF as described above and subsequently pulsed with 10 mg/ml peptide for 2 hours at 371C.
Generation and isolation of CAMEL-specific T cells
To generate CAMEL-specific T-cell lines, 20 Â 10 6 nonadherent PBMC of healthy donor 1 and 2 were incubated with autologous DC infected with Ad5F35-CAMEL or pulsed with the rCAMEL protein at ratios ranging between 5:1 and 10:1 at 2 Â 10 6 PBMC/well in 24-well plates containing IMDM (Invitrogen) with 5% pooled human AB serum (HS), AAG and antibiotics, supplemented with 10 ng/ml IL-7 (PeproTech) and 100 pg/ml IL-12 (Sigma-Aldrich, Zwijndrecht, The Netherlands). T-cell cultures were weekly restimulated as described above in IMDM with 5% HS, AAG and antibiotics, supplemented with 150 U/ml IL-2. At day 36, the T-cell line stimulated with DC infected with Ad5F35-CAMEL of healthy donor 1 was seeded at 1 cell/well in 96-well U-bottom plates to generate T-cell clones. Each well contained 10 5 irradiated, allogeneic PBMC, 5 Â 10 3 irradiated, allogeneic EBV-B cells, 5 Â 10 3 irradiated, autologous DC pulsed with 2 mg/ ml CAMEL and CAMEL 46-65 and 1 mg/ml leucoagglutinin (Sigma-Aldrich) and 150 U/ml IL-2. Growing clones were weekly restimulated as described above.
Tetramer staining
T cells (2 Â 10 5 ) were stained with PE-conjugated HLA-A*0201/CAMEL 1-11 tetramers (kindly provided by P Romero, Lausanne, Switzerland) in PBS containing 0.5% BSA and 0.02% NaN 3 for 30 minutes at room temperature (RT), followed by an additional incubation of 30 minutes at 41C with anti-CD8-FITC (Becton Dickinson, Mountain View, CA). Prior to the measurement, propidium iodide was added to a final concentration of 5 mg/ml to exclude dead cells during the analysis by flow cytometry (FACSCalibur, Becton Dickinson) using CellQuest software.
IFN-g ELISPOT assay
IFN-g ELISPOT assays were performed as described previously with small modifications. 42 Briefly, 96-well nylon Silent Screen plates (Nalge Nunc International Corporation, Rochester, NY) were coated with 100 ml of a mouse monoclonal antibody against human IFN-g (1-D1 K, Mabtech AB, Nacka, Sweden) diluted to 5 mg/ml in PBS overnight at 41C. Wells were washed several times with PBS and blocked with 50 ml/well IMDM/5% HS for 1 hour at 371C. T cells (1-2 Â 10 4 cells/well) were incubated with target cells (1-2 Â 10 4 cells/well) in duplicate. For blocking studies, target cells were preincubated with antibodies against HLA class I (w6/32) or HLA class II (IC-2) for 30 minutes at 371C. To inhibit proteasomal activity, target cells were pretreated with 10 mM lactacystin (Sigma-Aldrich) for 2 hours at 371C. After 4-hour incubation with 10 mg/ml peptide, target cells were washed and fixed with 1% paraformaldehyde to prevent further processing. After overnight incubation at 371C, the plates were washed several times with PBS/0.05% Tween-20 and subsequently incubated with 100 ml of a biotinylated antibody against human IFN-g (7-B6-1-biotin, Mabtech) diluted at 0.3 mg/ml in PBS for 2 hours at RT. Wells were washed several times and incubated with 100 ml streptavidin-alkaline phosphatase (Mabtech) in PBS/0.5% FCS for 1 hour at RT. After several washes, wells were incubated with 100 ml substrate solution (AP-conjugate substrate kit; Bio-Rad, Hercules, CA) for 15-30 minutes at RT. The colorimetric reaction was stopped under running tap water and spots were counted using computer-assisted video image analysis with KS ELI-SPOT software (Carl Zeiss Vision GmbH, Hallbergmoos, Germany). 4 T cells in a 96-well flat bottom plate overnight at 371C in the presence of 150 U/ml IL-2. To inhibit proteasomal activity, target cells were pretreated with 10 mM lactacystin (Sigma-Aldrich) for 2 hours at 371C. After 4-hour incubation with 10 mg/ml peptide, target cells were washed and fixed with 1% paraformaldehyde to prevent further processing. The release of IFNg, TNFa, IL-2, IL-4, IL-5 and IL-10 by the T cells in the supernatant was analyzed using the Human Th1/Th2 Cytokine Cytometric Bead Array (CBA) assay according to the manufacturer's instructions (BD Biosciences, Franklin Lakes, NJ).
Granzyme B ELISA
The release of granzyme B in the culture supernatant was measured by ELISA, according to the manufacturer's instructions (CLB, Amsterdam, The Netherlands). Briefly, 96-well ELISA plates were coated overnight at RT with monoclonal antibodies directed against human granzyme B. Wells were washed several times with PBS/ 0.02% Tween-20 and subsequently blocked with kit buffer for 1 hour at RT. Wells were incubated with serial dilutions of culture supernatants for 1 hour at RT. After several washes, 100 ml biotinylated antibody against human granzyme B was added for 1 hour at RT. Wells were washed several times and incubated with streptavidin-poly-HRP conjugate for 30 minutes at RT. After washing, wells were incubated with 100 ml substrate solution. The reaction was stopped by addition of 100 ml 0.18 M sulfuric acid solution and OD450 was measured using a microplate reader (Wallac, Turku, Finland).
Results
Induction of HLA-A*0201-restricted CAMEL/NY-ESO-ORF2 1-11 -specific CD8 þ T cells by DC infected with Ad5F35-CAMEL Nonadherent PBMC from two HLA-A*0201-positive healthy donors (donors 1 and 2) were incubated with autologous DC infected with Ad5F35-CAMEL or pulsed with recombinant CAMEL protein (rCAMEL). T-cell cultures were weekly restimulated with autologous DC infected with Ad5F35-CAMEL or pulsed with rCAMEL protein and tested for the presence of CD8 þ T cells specific for the previously described HLA-A*0201-binding epitope CAMEL/NY-ESO-ORF2 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] 33 by tetramer staining. In both donor 1 (Fig 1) and donor 2 (Fig 2) , CAMEL/NY-ESO-ORF2 1-11 -specific CD8 þ T cells Generation of a CAMEL 46-54 -specific CD8 þ T-cell line by DC infected with Ad5F35-CAMEL The T-cell cultures at days 14 and 21 that were shown to contain CAMEL/NY-ESO-ORF2 1-11 -specific T cells after stimulation with DC infected with Ad5F35-CAMEL were also screened for T cells specific for unknown CAMEL epitopes in IFN-g ELISPOT assays. The Ad5F35-CAMEL-stimulated T-cell cultures were tested against autologous DC infected with Ad5F35-CAMEL and, as a control, empty Ad5F35-vector and autologous DC pulsed with mixes of overlapping peptides covering the entire CAMEL protein sequence. Peptide mix 1 contained three 20-mer peptides (CAMEL [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , CA-MEL [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] and CAMEL [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] ) with predicted binding motifs for various HLA alleles (data not shown), whereas peptide mixes 2 and 3 each consisted of four overlapping 22-mer peptides covering aa 21-72 and aa 61-109 of the CAMEL protein sequence, respectively. At day 14, T-cell cultures of donor 1 (Fig 3a) and donor 2 (Fig 3b) both produced IFN-g upon stimulation with DC infected with Ad5F35-CAMEL as well as Ad5F35-empty, demonstrating the presence of adenovirus-specific T cells. T cells specific for CAMEL-derived peptides could not be detected in both donors at day 14. At day 21, the adenovirus-specific T cells were hardly detectable in the T-cell cultures of both donors, as demonstrated by low numbers of IFN-g spots produced upon stimulation with DC infected with Ad5F35-empty. The T-cell culture of donor 1, however, specifically released high amounts of IFN-g upon stimulation with DC infected with Ad5F35-CAMEL (Fig 3a) , strongly suggesting the presence of CAMEL-specific T cells. The release of IFN-g was also observed upon stimulation with DC pulsed with mixes of CAMEL-derived peptides, further supporting the presence of CAMEL-specific T cells in the Ad5F35-CAMELstimulated T-cell culture of donor 1.
To determine the epitope(s) recognized by the Ad5F35-CAMEL-stimulated T-cell culture of donor 1, recognition of DC pulsed with the single CAMEL peptides was measured in an IFN-g ELISPOT assay. As shown in Figure 4a , two partially overlapping peptides, CAMEL and CAMEL [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] , stimulated IFN-g production by the Ad5F35-CAMEL-stimulated T-cell line. Recognition of these 22-and 20-mer peptides was inhibited by anti-HLA class I, but not by anti-HLA class II, antibodies strongly suggesting the presence of CD8 þ T cells specific for a previously unknown HLA-class I-binding CAMEL epitope. Screening the CAMEL and CAMEL 46- 
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þ T cells induced by Ad5F35-CAMEL-infected DC EH Slager et al presence of two predicted HLA-B7-binding motifs: APRGVRMAV at aa 46-54 and GVRMAVPLL at aa 49-57. Two 9-mer peptides containing the predicted HLA-B7-binding motifs (CAMEL [46] [47] [48] [49] [50] [51] [52] [53] [54] and CAMEL 49-57 ) were synthesized and tested for recognition by the Ad5F35-CAMEL-stimulated T-cell line of donor 1. Figure 4b demonstrates the specific release of IFN-g upon stimulation with DC pulsed with CAMEL 46-54 , but not CAMEL [49] [50] [51] [52] [53] [54] [55] [56] [57] , indicating that CD8 þ T cells specific for a new HLA-B7-binding CAMEL [46] [47] [48] [49] [50] [51] [52] [53] [54] epitope were induced by DC infected with Ad5F35-CAMEL.
Crosspresentation of CAMEL 46-54 into HLA-B7 by pulsing antigen-presenting cells with long synthetic peptides
Pulsing DC with the long 22-and 20-mer CAMEL and CAMEL [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] peptides clearly leads to processing and presentation of the epitope CAMEL 46-54 into HLA-B7 (Fig 4a) . We next tested whether crosspresentation in HLA class I also occurs in nonprofessional antigenpresenting EBV-B cells. HLA-B7-expressing DC and EBV-B cells were pulsed with rCAMEL protein, the long 22-and 20-mer CAMEL and CAMEL [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] peptides or the minimal CAMEL 46-54 peptide and were subsequently tested for recognition by the Ad5F35-CAMELstimulated T-cell line of donor 1. To minimize the possibility of degradation of the 20-and 22-mer peptides by serum proteases, experiments were performed in serum-free conditions. 43, 44 Both DC and EBV-B cells pulsed with the long CAMEL and CAMEL [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] peptides were clearly recognized by the Ad5F35-CAMELstimulated T-cell line (Fig 5a) . Crosspresentation of the long synthetic peptides in HLA class I proved very efficient, since DC and EBV-B cells pulsed with these peptides for 4 hours were able to stimulate the Ad5F35-CAMEL-stimulated T-cell line to similar levels as DC and EBV-B cells exogenously pulsed with the minimal CAMEL [46] [47] [48] [49] [50] [51] [52] [53] [54] peptide. These data also show that crosspresentation of long synthetic peptides in HLA class I is more efficient than crosspresentation of the full-length protein, since DC and EBV-B cells pulsed with the rCAMEL protein were not recognized by the Ad5F35-CAMEL-stimulated T-cell line. DC and EBV-B cells pulsed with rCAMEL protein, however, were clearly recognized by an HLA-DR3-restricted, CAMEL 14-33 -specific CD4 þ T-cell clone (Fig 5b) , demonstrating efficient processing and presentation of rCAMEL protein in HLA class II. As shown in Figure 6a , recognition of EBV-B cells pulsed with the long CAMEL peptide by the Ad5F35-CAMEL-stimulated T-cell line was not reduced upon treatment with lactacystin, whereas recognition of EBV-B cells pulsed with a long PRAME 98-124 peptide by an HLA-A*0201-restricted, PRAME 100-108 -specific CD8 þ T-cell clone was strongly inhibited. These experiments strongly suggest proteasome-independent processing of the CAMEL [46] [47] [48] [49] [50] [51] [52] [53] [54] epitope. This is supported by in vitro experiments, demonstrating disruption of the CAMEL 46-54 epitope due to the presence of major proteasome cleavage sites at positions 50 and 53 (data not shown).
Isolation of HLA-B7-restricted CAMEL/NY-ESO-ORF2 46-54 -specific CD8 þ T-cell clones
To obtain CAMEL 46-54 -specific CD8 þ T-cell clones, the Ad5F35-CAMEL-stimulated T-cell line of donor 1 was (b) HLA-A*0201-expressing EBV-B cells were pretreated with 10 mM lactacystin for 2 hours at 371C and pulsed with the 9-mer PRAME 100-108 and 27-mer PRAME 98-124 peptides (10 mg/ml) for 4 h at 371C. Target cells (2 Â 10 4 cells/well) were incubated together with PRAME 100-108 -specific CD8 þ T cells (2 Â 10 4 cells/well) in a 96-well plate overnight at 371C. Release of IL-4 in the culture supernatant was analyzed by ELISA. Fig 7) as well as melanoma cell line FM6 (HLA-B7-pos, LAGE/NY-ESO-1-pos, Fig 8) , indicating that the CAMEL/NY-ESO-ORF2 [46] [47] [48] [49] [50] [51] [52] [53] [54] epitope is a naturally processed HLA-B7-binding epitope shared by the alternatively translated CAMEL and NY-ESO-ORF2 proteins.
Discussion
Since previous studies have shown that CD4 þ T helper cells contribute to the efficient induction of CD8 þ T-cellmediated antitumor reponses, [17] [18] [19] 45 delivery of the fulllength tumor antigen might be more successful in immunotherapy than delivery of HLA class I-binding antigenic peptides. Moreover, in contrast to HLA class Ibinding peptides, delivery of the full-length tumor antigen is broadly applicable to patients with different HLA types. Although several studies have demonstrated generation of tumor-specific CD8 þ T cells by DC infected with Ad5 vectors encoding tumor antigens, [20] [21] [22] infection of DC with Ad5 vectors is rather inefficient due to lack of CAR, the high-affinity ligand for the fiber of Ad5. The chimeric Ad5F35 vector is a modified Ad5 vector, containing the fiber shaft and knob of Ad35, which binds another, yet unknown, surface receptor. The Ad5F35 vector has been shown to infect DC efficiently and therefore, higher expression levels of the transgene are achieved. 26, 27 In this study, we tested the in vitro induction of CAMEL/NY-ESO-ORF2-specific T cells by DC infected with a modified Ad5 vector containing a chimeric Ad5/35 fiber.
Upon stimulation with DC infected with the chimeric Ad5F35-CAMEL vector, CD8 þ T cells specific for the previously identified CAMEL/NY-ESO-ORF2 1-11 epitope were induced in two healthy donors. In one healthy donor, also CD8 þ T cells specific for a new HLA-B7 binding CAMEL [46] [47] [48] [49] [50] [51] [52] [53] [54] 
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þ T cells induced by Ad5F35-CAMEL-infected DC EH Slager et al leads to more efficient processing and presentation of CAMEL epitopes into the HLA class II than HLA class I pathway.
The numbers of CAMEL/NY-ESO-ORF2 1-11 -specific CD8 þ T cells as induced by DC infected with Ad5F35-CAMEL, reached peak levels at day 14 and gradually decreased at day 21 to undetectable levels at day 28. The CAMEL 1-11 -specific CD8 þ T cells could not be detected in IFN-g ELISPOT assays (data not shown) due to frequencies that are too low to exceed the background number of spots. Despite several efforts, we have been unable to select the HLA-A*0201/CAMEL 1-11 -tetramerpositive CD8 þ T cells by FACS sorting and therefore, lysis of tumor cells by the CAMEL/NY-ESO-ORF2 1-11 -specific CD8 þ T cells could not be investigated. Previous experiments, however, have clearly shown lysis of HLA-A*0201-and CAMEL/NY-ESO-ORF2-expressing melanoma cell lines by an HLA-A*0201-restricted CAMEL/ NY-ESO-ORF2 1-11 -specific CTL clone. 33 The reason for the gradual decrease in numbers of CAMEL/NY-ESO-ORF2 1-11 -specific CD8 þ T cells upon repeated exposure to mature DC infected with Ad5F35-CAMEL is unknown, but might be explained by activation-induced cell death due to high levels of expression of the transgene.
Like the CAMEL/NY-ESO-ORF2 1-11 -specific CD8 þ T cells, adenovirus-specific T cells were transiently stimulated by DC infected with Ad5F35-CAMEL, reaching maximum numbers at day 14 in both healthy donors. The adenovirus-specific T cells not only recognized Ad5F35-infected cells, but also cells infected with the regular Ad5 vector (data not shown), indicating that some or all adenovirus-specific T cells were directed against Ad5-derived proteins. The gradual decrease in adenovirus-specific T cells upon repeated exposure to Ad5F35-infected DC is in contrast with other reports, showing that transgene-specific T cells were not induced or overgrown by adenovirus-specific T cells. 46, 47 In these studies, however, Ad2 and Ad5 constructs were used for gene transfer into DC. Therefore, as speculated for the CAMEL/NY-ESO-ORF2 1-11 -specific CD8 þ T cells, the adenovirus-specific T cells might disappear due to activation-induced cell death, mediated by mature DC expressing high levels of adenoviral proteins.
Pulsing of nonprofessional (EBV-B) and professional (DC) antigen-presenting cells with long synthetic 22-and 20-mer CAMEL and CAMEL [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] peptides led to efficient processing and presentation of the 9-mer CAMEL/NY-ESO-ORF2 46-54 epitope into HLA-B7, which could not be inhibited by treatment with lactacystin. This strongly suggests proteasome-independent processing and presentation of the CAMEL/NY-ESO-ORF2 46-54 epitope in HLA-B7. Crosspresentation of CAMEL/NY-ESO-ORF2 46-54 into HLA-B7 could not be measured after pulsing EBV-B cells and DC with the rCAMEL protein, whereas these cells were clearly recognized by HLA-DR3-restricted CAMEL 14-33 -specific CD4 þ T cells. These data demonstrate that delivery of the CAMEL antigen by infection with the Ad5F35 vector or by pulsing with long synthetic peptides leads to efficient processing and presentation of CAMEL epitopes into the HLA class I pathway, whereas delivery of the full-length rCAMEL protein leads to efficient processing and presentation into the HLA class II pathway. Since CD8 þ T cells have been suggested to be the main effector cells in tumor cell lysis, DC infected with the Ad5F35 vector encoding the tumor antigen or DC pulsed with long synthetic tumor antigenic peptides might be more successful in future T-cell-based immunotherapies than DC pulsed with the full-length tumor protein.
Our data show successful induction of CAMEL/NY-ESO-ORF2-specific CD8 þ T cells in healthy donors by stimulation with DC infected with Ad5F35-CAMEL. CAMEL and NY-ESO-ORF2 are so-called cancer-testis antigens that are expressed in various tumor types, but silent in normal tissues, except for testis. The lack of expression of CAMEL and NY-ESO-ORF2 in normal tissues suggests that in healthy donors, primary CD8 þ Tcell-mediated immune responses were induced by DC infected with Ad5F35-CAMEL. Since such immune responses could not be generated by DC pulsed with rCAMEL protein, our data support further investigation of the Ad5F35 vector as a vehicle for gene transfer into DC for the efficient induction of tumor antigen-specific CD8 þ T cells in vivo.
